Please assess the completion status of the following clinical trial:

Trial Title: Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (18 - 64 years) critically ill patients diagnosed with transfusion related acute lung injury (TRALI), at the time of enrollment or maximum 6 hours before, according to the National Heart, Lung and Blood Institute (NHLBI) Working Group definitions and or the Canadian Consensus Conference criteria (29, 30) as the following criteria;~  * No evidence of ALI prior to transfusion.~ * Onset of ALI ≤ 6 hours following cessation of transfusion.~ * Hypoxemia, defined as the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mmHg or oxygen saturation ≤ 90% on room air.~ * Radiographic evidence of bilateral infiltrates.~ * No evidence of left atrial hypertension.~Exclusion Criteria:~* Pregnancy or breastfeeding.~* Hypernatremia or known hypersensitivity to the study drug.~* Parenteral nutrition (total/partial) containing vitamin C.~* Active renal stone or history of urolithiasis.~* Acute Kidney Injury.~* Glucose 6 phosphate dehydrogenase deficiency, iron and copper storage diseases.~* Immunocompromised patients (cancer or patients on immunosuppressive drugs).~* Moribund patient not expected to survive 24 hours .~* Home mechanical ventilation (via tracheotomy or noninvasive) except for Continuous Positive Airway Pressure/ Bilevel Positive Airway Pressure (CPAP/BIPAP) used only for sleep-disordered breathing .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- ASTRALI Group (Type: EXPERIMENTAL): ASTRALI (AScorbic acid in TRALI) group (n=40)
- Control Group (Type: PLACEBO_COMPARATOR): Control group (n=40)

Based on this trial design, predict the completion outcome and termination type (if applicable).